<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956864</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00047888</org_study_id>
    <nct_id>NCT01956864</nct_id>
  </id_info>
  <brief_title>Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer</brief_title>
  <official_title>A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a high dose of
      vitamin D (VD) in patients with cirrhosis. The investigator hypothesizes that high dose VD
      will be safe and well-tolerated in adults with cirrhosis, and will inhibit the inflammatory
      and proliferative events that cause progression of cirrhosis to hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be done in two phases. The first phase is being done to find the highest dose
      of VD that can be tolerated, in other words taken without causing severe side effects. The
      second phase is a 6 month treatment with the dose determined to be safe in the first phase,
      to investigate general health benefits and the potential to reduce the development of
      Hepatocellular carcinoma (HCC), also known as liver cancer. Improvement of general health
      will be determined by interviews with patients, markers in the blood for response to VD, bone
      remodeling, inflammation, and evidence of HCC on routine imaging.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either
    site. Funding lapsed.
  </why_stopped>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">February 11, 2016</completion_date>
  <primary_completion_date type="Actual">February 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants on high dose Vitamin D with adverse events</measure>
    <time_frame>after 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the expression of serum and imaging biomarkers</measure>
    <time_frame>After 6 months on vitamin D regimen</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose VD 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose VD 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose VD 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose VD 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose VD 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VD 6 Month Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.</description>
    <arm_group_label>Dose VD 1</arm_group_label>
    <arm_group_label>Dose VD 2</arm_group_label>
    <arm_group_label>Dose VD 3</arm_group_label>
    <arm_group_label>Dose VD 4</arm_group_label>
    <arm_group_label>Dose VD 5</arm_group_label>
    <arm_group_label>VD 6 Month Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All subjects between the ages of 18 and 75 with cirrhosis of any etiology followed at
             the Georgetown Transplant Institute, Washington, DC, will be offered entry into this
             study. The diagnosis of cirrhosis will be based on clinical, imaging or histological
             studies.

          2. No evidence of HCC on entry imaging study ( if liver nodules are present, these should
             be classified as LIRADS 1-3 only).

          3. Model for End Stage Liver Disease (MELD) score under 22 (a MELD score over 22 would
             predict a 3 month mortality rate of approximately 20%).

          4. Not currently participating in another intervention study.

          5. Not pregnant or lactating, and willing to use effective contraception during study
             period.

          6. Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          7. Ability to provide written informed consent according to national/local regulations

        Exclusion Criteria:

          1. Any diagnosis of kidney stones

          2. A diagnosis of granulomatous diseases (e.g., sarcoidosis), active chronic fungal or
             mycobacterial infections (e.g., tuberculosis, histoplasmosis, coccidioidomycosis,
             blastomycosis, berylliosis, or Wegener's granulomatosis) in the past 6 months

          3. A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism
             in the past 5 years

          4. A diagnosis of severe kidney disease, e.g., chronic renal failure, in the past 6
             months

          5. A diagnosis of unexplained hypercalcemia in the past 6 months

          6. Any diagnosis of osteoporosis with physician recommendation for treatment of low bone
             mass

          7. A diagnosis of two or more low trauma fractures in the past 6 months

          8. A diagnosis of a medical condition requiring treatment with VD (e.g., osteomalacia) in
             the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirti Shetty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sibley Memorial Hospital /Johns Hopkins University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

